Skip to main content
IXHL
NASDAQ Life Sciences

Incannex Q1 Loss Narrows to $1.9M; Material Weakness Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.98
Mkt Cap
$24.776M
52W Low
$1.96
52W High
$14.91
52W Position info
1.0% above low
Off High info
87% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

IXHL is trading near its 52-week low of $1.96 (1.0% above the low).

Summary

Incannex posted a $1.9M net loss for the September 2026 quarter with $68.3M of cash and no new financing, while repeating that its internal control over financial reporting remains ineffective due to an unremediated segregation-of-duties material weakness.


Key Events · Earnings and Guidance · IXHL

  • Q1 Net Loss Narrows to $1.9M

    Net loss was $1.9M for the three months ended September 30, 2026, versus $6.4M a year earlier, as general and administrative expense fell to $2.3M from $5.7M on lower stock-based compensation ($0.3M vs $2.6M).

  • Cash Flat at $68.3M, No New Financing

    Cash and cash equivalents were $68.3M at September 30, 2026 versus $67.7M at June 30, 2026, and no cash came from financing activities in the quarter; management says existing cash funds operations for at least twelve months.

  • Material Weakness Still Unremediated

    Management concluded disclosure controls and internal control over financial reporting were not effective at September 30, 2026 because the CFO initiates, oversees and approves financial reporting without independent review and segregation of duties is not achieved; the weakness was previously disclosed in the September 25, 2026 10-K.

  • Warrant Remeasurement Adds $0.9M Non-Cash Gain

    The change in fair value of the March 2026 common warrant liability produced $0.9M of other income, cutting the liability to $3.2M from $4.1M; this is a non-cash mark-to-market entry, not new dilution or a cash inflow.


Analysis · IXHL · Life Sciences

The quarter itself is quiet: net loss fell to $1.9M from $6.4M a year ago, mostly because stock-based compensation dropped to $0.3M from $2.6M, and cash held roughly flat at $68.3M with no financing raised. What keeps this at a high score is the controls disclosure: management again concluded disclosure controls and internal control over financial reporting were not effective at September 30, 2026 because the CFO initiates, oversees and approves financial reporting without independent review and segregation of duties is not achieved. That weakness was first disclosed in the September 25, 2026 10-K and remains unremediated, so the company is still operating without effective internal review over its numbers. The $0.9M warrant fair-value gain is non-cash and reflects remeasurement of the March 2026 warrants, not new dilution or cash.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IXHL was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.8M. The 52-week trading range was $1.96 to $14.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IXHL - Latest Insights

IXHL
Sep 25, 2026, 8:41 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.40
Real-time Price: $1.98 info
Change: -$1.42 (-42%) info
Market Cap: $24.776M info
IXHL
Aug 25, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $1.98 info
Change: -$1.35 (-41%) info
Market Cap: $24.776M info
IXHL
Aug 11, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $1.98 info
Change: -$1.35 (-41%) info
Market Cap: $24.776M info
IXHL
Jul 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.98 info
Change: -$1.08 (-35%) info
Market Cap: $24.776M info
IXHL
Jun 25, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.54
Real-time Price: $1.98 info
Change: -$1.56 (-44%) info
Market Cap: $24.776M info